Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05949684
Other study ID # CA056-025
Secondary ID 2022-500430-29-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 24, 2023
Est. completion date March 11, 2030

Study information

Verified date June 2024
Source Bristol-Myers Squibb
Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Phone 855-907-3286
Email Clinical.Trials@bms.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date March 11, 2030
Est. primary completion date June 25, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Participant has documented diagnosis of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of = 3.5 IPSS-R score) confirmed via bone marrow aspirate and:. i) < 5% blasts in bone marrow and < 1% blasts in peripheral blood. - Participant is not transfusion dependent (NTD) based on IWG2018 criteria. - Participant has never received treatment with an erythropoiesis stimulating agent (ESA). - Participant has a baseline endogenous serum erythropoietin (sEPO) level of = 500 U/L. - Participant has symptoms of anemia:. i) Participant records a severity score of "moderate" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness performed during the screening period. - Participant has a mean baseline Hb concentration prior to randomization of = 9.5 g/dL. Mean Hb is defined as the mean of all central/ local/ pretransfusion available Hb measurements during the 16 weeks prior to randomization (with a minimum of 2 measurements at least 1 week apart). Only Hb levels > 21 days following a transfusion are acceptable. The last measurement must be within 35 days of randomization. Exclusion Criteria - Participant with secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases). - Participant with known history of diagnosis of AML. - Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to randomization. - Participant with a history of pure red cell aplasia and/or antibody against erythropoietin. - Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Luspatercept
Specified dose on specified days
Epoetin Alfa
Specified dose on specified days

Locations

Country Name City State
Argentina Centro Mdico "Barrio Parque" Buenos Aires
Argentina Local Institution - 0012 Buenos Aires
Argentina Local Institution - 0009 Ciudad Autónoma de Buenos Aires
Australia Blacktown Hospital Blacktown New South Wales
Australia Royal Prince Alfred Hospital Camperdown New South Wales
Australia Monash Health Clayton Victoria
Australia Local Institution - 0254 Coffs Harbour New South Wales
Australia Local Institution - 0246 Gold Coast Queensland
Australia Austin Health Heidelberg Victoria
Brazil Hospital Universitario Walter Cantidio Fortaleza Ceará
Brazil Hospital São Lucas da PUCRS Porto Alegre Rio Grande Do Sul
Brazil HEMORIO Rio de Janeiro
Brazil Hospital das Clinicas FMUSP São Paulo
Canada Tom Baker Cancer Center Calgary Alberta
Canada Victoria Hospital & Children's Hospital - London Health Sciences Centre London Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada Local Institution - 0112 Vancouver British Columbia
China Beijing Peking Union Medical College Hospital Beijing Beijing
China Peking University People's Hospital Beijing Beijing
China The First Hospital of Jilin University Changchun Jilin
China Xiangya Hospital Central South University Changsha Hunan
China West China Hospital of Sichuan University Cheng Du Sichuan
China The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing
China Local Institution - 0096 Fuzhou Fujian Fujian
China Local Institution - 0031 Guangzhou Guangdong
China The first Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang
China The First Hospital of Harbin Harbin Heilongjiang
China Anhui Provincial Hospital Hefei Anhui
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi
China Jiangsu Province Hospital Nanjing Jiangsu
China The Affiliated Hospital of Qingdao University Qingdao Shandong
China Local Institution - 0218 Shanghai Shanghai
China The First Hospital of China Medical University Shenyang Liaoning
China Institute of hematology&blood disease hospital Tianjin Tianjin
China The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang
China Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei
China The First Affiliated hospital of Xiamen University Xiamen Fujian
China Shaanxi provincial people's hospital Xian Shaanxi
China People's Hospital of Henan Province Zhengzhou Henan
Colombia Local Institution - 0147 Medellin Antioquia
Colombia Local Institution - 0149 Montería Córdoba
Colombia Local Institution - 0152 Valledupar Cesar
Czechia Local Institution - 0080 Brno Brno-mesto
Czechia Fakultni nemocnice Ostrava Ostrava Moravskoslezský Kraj
Czechia Vseobecna fakultni nemocnice v Praze Praha 2
France Chu Grenoble Alpes La Tronche Isère
France Centre Hospitalier Universitaire de Nice - Hôpital l'Archet Nice Alpes-Maritimes
France Hôpital Saint-Louis Paris
France CHU Bordeaux Haut-Leveque Pessac Aquitaine
France Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE Toulouse
France Local Institution - 0019 Tours Indre-et-Loire
France Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois Vandoeuvre lès Nancy Lorraine
France Local Institution - 0248 Villejuif Val-de-Marne
Germany Local Institution - 0028 Berlin
Germany Praxis fur Hamatologie und Onkologie Berlin
Germany Universitaetsklinikum Duesseldorf Düsseldorf
Germany Local Institution - 0261 Erding Bayern
Germany Local Institution - 0251 Jena Thüringen
Germany Local Institution - 0250 Kempten Bayern
Germany Local Institution - 0168 Koblenz Rheinland-Pfalz
Germany Universitätsklinikum Leipzig Leipzig Sachsen
Germany Local Institution - 0255 Lübeck
Germany Local Institution - 0259 Münster Nordrhein-Westfalen
Germany Kliniken Ostalb, Stauferklinikum Mutlangen
Germany Gemeinschaftspraxis Dr. med. Björn Schöttker & Dominik Pretscher Würzburg
Greece University Hospital of Alexandroupolis Alexandroupolis
Greece General Hospital of Athens "G. Gennimatas" Athens Attikí
Greece Attikon General University Hospital Chaidari Attikí
Greece Local Institution - 0132 Patras Acha?a
Greece Local Institution - 0242 Patras Acha?a
Hungary Semmelweis Egyetem Budapest
Hungary Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelointézet Eger Heves
Hungary Szabolcs Szatmár Bereg Vármegyei Oktatókórház Nyiregyhaza Szabolcs-Szatmár-Bereg
India Local Institution - 0243 Ahmedabad Gujarat
India Local Institution - 0177 Bengaluru Karnataka
India Local Institution - 0178 Bhubaneswar Odisha
India Local Institution - 0185 Hyderabad
India Local Institution - 0186 New Delhi
India Local Institution - 0193 New Delhi Delhi
India Local Institution - 0235 New Delhi Delhi
Italy IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola Bologna
Italy Azienda Ospedaliera Universitaria Careggi Firenze Toscana
Italy ASST Grande Ospedale Metropolitano Niguarda Milan Milano
Italy Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Lombardia
Italy Local Institution - 0076 Reggio Calabria
Italy Local Institution - 0244 Roma
Italy Local Institution - 0256 Rome Lazio
Italy Humanitas Rozzano Milano
Italy Azienda Ospedaliera Ordine Mauriziano di Torino Torino Piemonte
Italy Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma Verona
Mexico Hematológica Alta Especialidad SC, consultorio 830 Huixquilucan
Mexico Local Institution - 0142 Mexico City Distrito Federal
Mexico Unidad Médica Onco-hematológica Puebla
Poland Uniwersyteckie Centrum Kliniczne Gdansk
Poland Pratia Onkologia Katowice Katowice
Poland Specjalistyczny Szpital im. dra Alfreda Sokolowskiego w Walbrzychu Walbrzych Dolnoslaskie
Poland MTZ Clinical Research powered by Pratia Warsaw
Puerto Rico Auxilio Mutuo Cancer Center San Juan
Puerto Rico Local Institution - 0237 San Juan
Spain Hospital Universitari Vall d'Hebron Barcelona Barcelona [Barcelona]
Spain Local Institution - 0199 Granada
Spain Institut Català d'Oncologia - L'Hospitalet L'Hospitalet de Llobregat Catalunya [Cataluña]
Spain Local Institution - 0252 Madrid
Spain Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca Salamanca
Spain Hospital Clinico de Valencia Valencia Valenciana, Comunitat
United States Our Lady of the Lake RMC Baton Rouge Louisiana
United States American Oncology Partners of Maryland, PA Bethesda Maryland
United States Community Cancer Institute Clovis California
United States The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center Columbus Ohio
United States John Muir Medical Center - Concord Campus Concord California
United States Pontchartrain Cancer Center Covington Louisiana
United States Halifax Health Medical Center Daytona Beach Florida
United States Local Institution - 0230 Daytona Beach Florida
United States Local Institution - 0098 Fort Collins Colorado
United States Florida Cancer Specialists - South Fort Myers Florida
United States Compassionate Cancer Care Medical Group Fountain Valley California
United States Local Institution - 0095 Fresno California
United States John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey
United States Hartford Hospital (HH) Hartford Connecticut
United States Hattiesburg Clinic Hematology/Oncology Hattiesburg Mississippi
United States Local Institution - 0240 Honolulu Hawaii
United States University of Texas MD Anderson Cancer Center Houston Texas
United States Baptist MD Anderson Cancer Center Jacksonville Florida
United States Kadlec Clinic Hematology and Oncology Kennewick Washington
United States University of Tennessee Medical Center Knoxville Tennessee
United States D&H Cancer Research Center LLC Margate Florida
United States Yale-New Haven Hospital New Haven Connecticut
United States Local Institution - 0097 New Orleans Louisiana
United States Local Institution - 0247 Orange California
United States Ventura County Hematology Oncology Specialists Oxnard California
United States Local Institution - 0232 Pikeville Kentucky
United States BRCR Global Plantation Florida
United States Local Institution - 0236 Richmond Virginia
United States Blue Ridge Cancer Care Roanoke Virginia
United States Metro-Minnesota Community Clinical Oncology Saint Louis Park Minnesota
United States Florida Cancer Specialists - North Saint Petersburg Florida
United States Local Institution - 0213 Seattle Washington
United States Orchard Healthcare Research Inc. Skokie Illinois
United States Local Institution - 0238 Tamarac Florida
United States Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Canada,  China,  Colombia,  Czechia,  France,  Germany,  Greece,  Hungary,  India,  Italy,  Mexico,  Poland,  Puerto Rico,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with lower-risk non-transfusion dependent myelodysplastic syndromes (NTD-MDS) who converted to Transfusion Dependence (TD) during any continuous 16-week interval within the 96-week treatment period TD is defined as = 3 red blood cells (RBC) units/16 weeks assessed by International Working Group (IWG) 2018. Up to Week 96
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.5 grams/deciliter (g/dL) in any continuous 16-week interval within the 48 week Treatment Period in the absence of transfusion Up to Week 48
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion Up to Week 48
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion From Week 49 to Week 96
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion Up to Week 96
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion Up to Week 48
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion From Week 49 to Week 96
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.0 g/dL in any continuous 24-week interval within the 48-week and 96-week treatment period in the absence of transfusion Up to Week 96
Secondary Mean Hb change over fixed 24-week periods compared to the baseline Hb Baseline, Week 24, Week 48, Week 72, Week 96
Secondary Number of participants with an increase from baseline in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 96-week treatment period in the absence of transfusion Up to Week 96
Secondary Number of participants with TD by week 48 Up to Week 48
Secondary Time to TD (IWG 2018 defined as = 3 RBC units/16 weeks) during any continuous 16-week interval until the end of study Up to 5 years
Secondary Time from first Luspatercept dose to first RBC transfusion Up to 5 years
Secondary Duration of median hematologic improvement in erythroid response(mHI-E) in participants with an increase from baseline in mean Hb values of =1.5g/dL in any continuous 16-week interval within 48-week treatment period in absence of transfusion Up to Week 48
Secondary Duration of median hematologic improvement in erythroid response(mHI-E) in participants with an increase from baseline in mean Hb values of =1.5g/dL in any continuous 16-week interval within 96-week treatment period in absence of transfusion Up to Week 96
Secondary Time from first dose to first day of response (increase in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 48-week Treatment Period in the absence of transfusion) Up to Week 48
Secondary Time from first dose to first day of response (increase in mean Hb values of = 1.5 g/dL in any continuous 16-week interval within the 96-week Treatment Period in the absence of transfusion) Up to Week 96
Secondary Number of participants with RBC transfusion independence over at least a consecutive 24-week period Up to 5 years
Secondary Number of transfusions Up to 5 years
Secondary Number of transfusions visits/units Up to 5 years
Secondary Change from baseline in subscales of self-reported health-related quality-of-life (HRQoL) assessed by the Functional Assessment of Cancer Therapy - Anemia (FACT-An) Baseline, Up to 5 years
Secondary Change from baseline in self-reported HRQoL assessed by the European quality of life questionnaire 5-dimension (EQ-5D-5L) Baseline, Up to 5 years
Secondary Number of participants with adverse events (AEs) Up to Week 102
Secondary Number of participants with antidrug antibody (ADA) (positive or negative) Up to Week 102
Secondary Pharmacokinetics (PK): Serum concentration Up to Week 96
Secondary PK: Area under the plasma concentration time curve (AUC) Up to Week 96
Secondary Number of participants with a platelet response at Week 24, Week 48 and Week 96 Platelet response is defined as an increase from baseline in number of platelets to = 30 × 10^9/L at Week 24, Week 48 and Week 96. Up to Week 96
Secondary Number of participants with a neutrophil response at Week 24, Week 48 and Week 96 Neutrophil response is defined as an absolute increase from baseline of > 0.5 × 10^9/L neutrophils at Week 24, Week 48 and Week 96. Up to Week 96
Secondary Number of participants with acute myeloid leukemia (AML) progression Up to 5 years
Secondary Time to AML progression Up to 5 years
Secondary Number of participants with high risk myelodysplastic syndromes (MDS) progression Up to 5 years
Secondary Time to high-risk MDS progression Up to 5 years
Secondary Time from date of randomization up to death due to any cause Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Terminated NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1